Candriam SCA’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Candriam SCA’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-57,000	Closed	-$581K	–	851
2018 Q2	$581K	Hold	57,000	–	–	0.01%	680
2018 Q1	$741K	Hold	57,000	–	–	0.01%	631
2017 Q4	$1.02M	Sell	57,000 -106,000	-65%	-$2.21M	0.02%	583
2017 Q3	$4.09M	Sell	163,000 -64,000	-28%	-$1.49M	0.07%	306
2017 Q2	$5.47M	Buy	227,000 +107,000	+89%	+$2.37M	0.1%	232
2017 Q1	$2.31M	Buy	+120,000	New	+$1.89M	0.04%	416
2016 Q4	–	Sell	-60,000	Closed	-$781K	–	697
2016 Q3	$781K	Buy	60,000 +20,000	+50%	+$265K	0.02%	534
2016 Q2	$556K	Buy	+40,000	New	+$589K	0.01%	539

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Candriam SCA's PRTK Position: Q3 2018 in Review

Candriam SCA sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 57,000 shares — an estimated $581K sold.

Candriam SCA first reported a position in PRTK in Q2 2016 and held it in 8 quarters. The position peaked at $5.47M in Q2 2017. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

Candriam SCA reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Candriam SCA sold 57,000 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $581K.
Candriam SCA first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 8 quarters.
Candriam SCA's Paratek Pharmaceuticals, Inc. position peaked at $5.47M in Q2 2017.
105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Candriam SCA's 13F filing for Q3 2018, filed 7 Nov 2018.